Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ875MR)

This product GTTS-WQ875MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ875MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12762MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ6075MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CNTO 888
GTTS-WQ13302MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-06523435
GTTS-WQ4284MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB-054
GTTS-WQ11043MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MCLA-128
GTTS-WQ14200MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RG4934
GTTS-WQ4320MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ6212MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CR4098
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW